Pacific Edge reviews US pricing for new Cxbladder test, trading halted

Pacific Edge reviews US pricing for new Cxbladder test, trading halted
Pacific Edge says Cxbladder Triage Plus delivers “significant performance improvements” compared to its existing tests. (Image: Pacific Edge)
Rebecca Howard
Pacific Edge has been placed on a trade halt while it reviews draft gapfill or reimbursement rates for its new Cxbladder Triage Plus test from the US Centres for Medicare and Medicaid Services.“[It said it's] reviewing the prices and the associated documentation and needs time to assess the implications of them, consult with its advisers and industry partners, and prepare an announcement that provides context to investors.”Gapfill prices are proposed reimbursement rates for new or unpriced clinical diagnostic laboratory tests.Th...

More Markets

The pros and cons of Sky’s big deal
Markets

Eden Bradfield: The pros and cons of Sky’s big deal

You'd best hope streaming and advertising revenue make up for the $1 purchase.

Infratil and Ebos help drive NZ stocks higher
Markets Market Close

Infratil and Ebos help drive NZ stocks higher

Infrastructure investor helped the sharemarket end the week on a positive note.

Tom Raynel 25 Jul 2025
Bathurst fails to strike-out Talley's claims
Markets

Bathurst fails to strike-out Talley's claims

Talley's is alleging Companies Act breaches by its coal JV partner.

Pattrick Smellie 25 Jul 2025
New CFO for KMD Brands
Markets

New CFO for KMD Brands

Carla Webb-Sear has been appointed group chief financial officer for KMD Brands.She will join the group executive team on Aug 4 and report to Brent Scrimshaw, group chief executive and managing director.She joins KMD Brands from Qantas, where she was chief financial and strategy...

Staff reporters 25 Jul 2025